2 most recent filings and news items mentioning STOK. Updated every 60 seconds.
OfferingAug 3, 2026Neutral
Cantor Fitzgerald provided a legal opinion regarding Stoke Therapeutics' proposed purchase of its own common stock. The company filed a prospectus supplement on August 3, 2026 to facilitate a delayed or continuous offering.
View filing at SEC.gov →
OtherJun 30, 2026Positive
Stoke Therapeutics reported completing enrollment for the zorevunersen Phase 3 EMPEROR study involving 162 patients. The biotech firm plans a U.S. NDA submission in early 2027 and targets a potential launch by 2028.
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.